FIELD: medicine.
SUBSTANCE: namely endocrinology, ophthalmology, radiology, nuclear medicine and radionuclide diagnostics, method can be used to identify areas of accumulation of a radiopharmaceutical drug (RPD), corresponding to the lacrimal passages, using scintigraphic images of the head and neck of patients after radioiodine therapy. On the anterior projection of the scintigraphic image of the patient's head and neck, areas of RPD accumulation corresponding to the lacrimal passages are detected. The identified areas are outlined. At the same time, in order to identify areas of accumulation of RPD, corresponding to the lacrimal passages, zones of RPD accumulation in the submaxillary salivary glands - left and right - are visualized on the scintigraphic image. If the mentioned zones of RPD accumulation in the submaxillary salivary glands are not determined, visualize the zones of RPD accumulation in the parotid salivary glands - left and right. Their geometric centers are found with the subsequent selection of the upper and lower boundaries of the areas of RPD localization, corresponding to the lacrimal passages. In this case, the lower boundary of the location of this area is determined at a distance of 77.3± 6.0 mm from the line connecting the geometric centers of the zones corresponding to the submaxillary salivary glands, or at a distance of 27.6± 2.3 mm from the line connecting the geometric centers of the areas corresponding to the parotid salivary glands. The upper limit of the location of this area is determined at a distance of 97.1± 6.8 mm from the line connecting the centers of the zones corresponding to the submaxillary salivary glands, or at a distance of 47.4± 3.4 mm from the line connecting the centers of the zones corresponding to the parotid salivary glands.
EFFECT: accurate determination of the region of the lacrimal passages on scintigraphic images due to anatomical landmarks.
1 cl, 9 dwg, 1 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DETERMINING INDIVIDUAL ACTIVITY OF 131-IODINE FOR RADIOIODINE THERAPY OF THYROTOXICOSIS AND PREDICTION OF TIME FOR ACHIEVING A SAFE LEVEL OF 131-IODINE ACTIVITY IN THE PATIENT'S BODY AFTER ADMINISTERING INDIVIDUAL 131-IODINE ACTIVITY | 2019 |
|
RU2722568C1 |
METHOD FOR PREVENTION OF SECONDARY NARROWING AND OBSTRUCTION OF LACHRYMAL PASSAGES IN TREATING ONCOLOGICAL DISEASES | 2019 |
|
RU2712394C1 |
METHOD FOR CONTROLLING RADIO IODINE THYROID GLAND CARCINOMA METASTASES THERAPY DISEASES IN MAXILLOFACIAL AREA | 2006 |
|
RU2317115C1 |
METHOD FOR PREVENTING RADIATION INJURY OF GLANDS IN PERSON | 2020 |
|
RU2821523C1 |
METHOD FOR ASSESSING THE RISK OF RECURRENT DIFFERENTIATED THYROID CANCER AFTER RADIOIODINE THERAPY | 2020 |
|
RU2743275C1 |
METHOD FOR DRAINAGE OF LACRIMAL DUCTS DURING OBLITERATION OF MOUTH OF NASOLACRIMAL DUCT | 2023 |
|
RU2806975C1 |
IMPROVED USE OF BOTULINUM NEUROTOXIN IN THE TREATMENT OF SIALORRHEA | 2018 |
|
RU2778481C2 |
METHOD FOR PROBING THE LACHRYMAL PASSAGES WITH OBSTRUCTION OF THE MOUTH OF THE NASOLACRIMAL DUCT | 2021 |
|
RU2760995C1 |
METHOD FOR DIFFERENTIAL DIAGNOSIS OF MALIGNANT AND BENIGN PARATHYROID GLAND FORMATIONS IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM | 2020 |
|
RU2738305C1 |
METHOD OF COMBINED RADIONUCLIDE THERAPY OF DIFFERENTIATED THYROID CANCER WITH METASTATIC INVOLVEMENT OF LUNGS AND SKELETON | 2023 |
|
RU2824276C2 |
Authors
Dates
2023-12-19—Published
2022-08-02—Filed